Cantor Fitzgerald raised the firm’s price target on Avita Medical to $25 from $22 and keeps an Overweight rating on the shares. Avita Medical reported commercial revenue of $14.1M, representing year over year growth of 50%, the analyst tells investors in a research note. The firm is incrementally positive on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RCEL:
- AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
- Avita Medical Ltd (RCEL) Q4 Earnings Cheat Sheet
- AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
- Avita Medical named best idea for 2024 at Cantor Fitzgerald
- AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific